Andere talen BeiGene, Ltd. Deutsche Boerse AG

Aandelen

49B

KYG1146Y1017

Beurs gesloten - Deutsche Boerse AG Andere beurzen 08:20:01 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
10,7 ^EUR	0,00%		-2,73%	-13,71%

26/06	Beigene Insider verkocht aandelen ter waarde van $445.070, volgens een recente SEC filing	MT
20/06	Beigene Insider verkocht aandelen ter waarde van $368.162, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing	26/06
Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing	20/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	17/06
BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index	17/06
BeiGene présentera à l’EHA2024 de nouvelles données sur l’étude SEQUOIA évaluant la bithérapie BRUKINSA® plus vénétoclax dans le traitement de première intention de patients atteints de LLC/PLL à haut risque	15/06
EHA2024: BeiGene präsentiert neue Daten der SEQUOIA-Studie zu BRUKINSA® plus Venetoclax für die Erstlinienbehandlung von Hochrisiko-CLL/SLL	15/06
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma	14/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	14/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	14/06
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region	14/06
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501	12/06
Beigene Issues Shares Under Incentive Schemes	12/06
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy	10/06
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	04/06
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	28/05
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	28/05
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	28/05
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	28/05
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa	24/05
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	24/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BeiGene, Ltd. Deutsche Boerse AG

Aandelen

49B

KYG1146Y1017

Andere talen

Filters